EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Newly identified properties of known pharmaceuticals and myxobacterial small molecules revealed by screening for autophagy modulators

Janine Fichtner iD, Yan Yan Beer iD, H G Mauricio Ramm iD, Sabrina Mühlen iD, Frank Surup iD, Jennifer Herrmann iD, Toni Luise Meister iD, Stephanie Pfaender iD, Ursula Bilitewski iD, Mark Brönstrup iD, Rolf Müller, Manfred Wirth und 2 weitere

The FEBS Journal · 2025

DOI: 10.1111/febs.70243 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FEBS Journal, 2025. Verfasst von Janine Fichtner und 13 weiteren Autor:innen. Beteiligte Einrichtung: Systems-Oriented Immunology and Inflammation Research Group, Helmholtz Centre for Infection Research, Braunschweig, Germany. Hauptthemen laut MEDLINE: Autophagy, Myxococcales. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Helmholtz-Gemeinschaft, Faculty of Medicine and Institute of Biomedicine, University of Turku, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autophagy is a cellular degradation and recycling process important for maintaining cellular health and function. It is constitutively active at a low level in eukaryotic cells and can be induced by conditions of cellular stress, such as nutrient starvation. Moreover, autophagy plays an important role in diverse processes such as immunobiology, pathogen infection, ageing, and neurodegenerative and other diseases. Using a high‐content fluorescence assay for microtubule‐associated protein 1 light chain 3 beta (LC3B), a major player in the autophagic pathway, we screened a library of commercial drugs and natural products for activators and inhibitors of LC3B‐positive vesicle accumulation. Positive hits for known autophagy modulators included anisomycin, amphotericin B, carbonyl cyanide m‐chlorophenylhydrazone (CCCP) and cytochalasin D. Importantly, we identified several new autophagy modulators, such as aciclovir and myxobacterial vioprolides. Anisomycin, aciclovir and vioprolides promoted intracellular growth of Staphylococcus aureus , a bacterium that is known to be a target of autophagy. In contrast, anisomycin strongly inhibited influenza A virus and SARS‐CoV‐2 replication. Subsequently, we investigated the influence of these autophagy modulators in a cellular disease model of neuronal vacuolation and spinocerebellar degeneration (NVSD), which is associated with cysteine protease ATG4D mutations. We provide evidence that anisomycin and famciclovir, an aciclovir analogue, can normalise the elevated amount of LC3‐positive vesicles in mutant fibroblasts, highlighting their potential for the treatment of NVSD. Thus, the screening method enabled the identification of autophagy‐modulating compounds with therapeutic potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutophagyMyxococcalesHumansMicrotubule-Associated ProteinsSARS-CoV-2Staphylococcus aureusAnimalsAnisomycinSmall Molecule LibrariesVirus ReplicationAntiviral AgentsDrug Evaluation, Preclinical

Stichwörter der Autor:innen

ATG4DLC3anti‐infectivesautophagydrug repurposingdrug screeningnatural products

Substanzen

Microtubule-Associated ProteinsAnisomycinSmall Molecule LibrariesMAP1LC3B protein, humanAntiviral Agents

Autor:innen und Institutionen

  • Systems-Oriented Immunology and Inflammation Research Group, Helmholtz Centre for Infection Research, Braunschweig, Germany.
  • Institute of Biomedicine, University of Turku, Finland.
  • Department of Molecular Immunology, Ruhr University Bochum, Germany.
  • Department of Microbial Drugs, Helmholtz Centre for Infection Research, Braunschweig, Germany.
  • German Centre for Infection Research (DZIF), Partner site Hannover-Braunschweig, Germany.
  • Department of Pharmacy, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Saarland University, Saarbrücken, Germany.

ORCID-Profile: Janine Fichtner, Yan Yan Beer, H G Mauricio Ramm, Sabrina Mühlen, Frank Surup, Jennifer Herrmann, Toni Luise Meister, Stephanie Pfaender, Ursula Bilitewski, Mark Brönstrup, Eeva-Liisa Eskelinen, Ingo Schmitz

Förderung

  • Helmholtz-Gemeinschaft
  • Faculty of Medicine and Institute of Biomedicine, University of Turku
  • Deutsche Forschungsgemeinschaft
  • German Center for Infection Research
  • Helmholtz Association
  • Deutsches Zentrum für Infektionsforschung

Zitieren

APA

Fichtner, J., Beer, Y. Y., Ramm, H. G. M., Mühlen, S., Surup, F., Herrmann, J., Meister, T. L., Pfaender, S., Bilitewski, U., Brönstrup, M., Müller, R., Wirth, M., Eskelinen, E. L., & Schmitz, I. (2025). Newly identified properties of known pharmaceuticals and myxobacterial small molecules revealed by screening for autophagy modulators. The FEBS Journal. https://doi.org/10.1111/febs.70243

Vancouver

Fichtner J, Beer YY, Ramm HGM, Mühlen S, Surup F, Herrmann J, et al. Newly identified properties of known pharmaceuticals and myxobacterial small molecules revealed by screening for autophagy modulators. The FEBS Journal. 2025. doi:10.1111/febs.70243

BibTeX
@article{Fichtner2025,
  author = {Fichtner, Janine and Beer, Yan Yan and Ramm, H G Mauricio and Mühlen, Sabrina and Surup, Frank and Herrmann, Jennifer and Meister, Toni Luise and Pfaender, Stephanie and Bilitewski, Ursula and Brönstrup, Mark and Müller, Rolf and Wirth, Manfred and Eskelinen, Eeva-Liisa and Schmitz, Ingo},
  title = {Newly identified properties of known pharmaceuticals and myxobacterial small molecules revealed by screening for autophagy modulators},
  journal = {The FEBS Journal},
  year = {2025},
  doi = {10.1111/febs.70243}
}
Kostenlos starten →